{"id":"093b95f12369","type":"article","url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","title":"Hospitalisatieredenen en mortaliteitsrisico bij AF met dabigatran versus warfarine: RE-LY","title_en":"Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euz021","source_url":"https://doi.org/10.1093/europace/euz021","authors":["Aiman Alak","Stefan H Hohnloser","Mandy Fräßdorf","Paul Reilly","Michael Ezekowitz","Jeff S Healey","Martina Brueckmann","Salim Yusuf","Stuart J Connolly"],"significance":5,"published":"2019-07-01","source_date":"2019-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This RE-LY analysis characterized hospitalization patterns and their association with mortality in AF patients on dabigatran versus warfarin, showing that both cardiovascular and non-cardiovascular admissions predict poor outcomes.","created":"2026-07-03T10:28:01Z","updated":"2026-07-03T13:27:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"RE-LY-analyse naar hospitalisatieredenen en mortaliteitsrisico bij AF-patiënten behandeld met dabigatran versus warfarine.","abstract_original":"AIMS: Hospitalizations are common among patients with atrial fibrillation. This article aimed to analyse the causes and consequences of hospitalizations occurring during the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. METHODS AND RESULTS: The RE-LY database was used to evaluate predictors of hospitalization using multivariate regression modelling. The relationship between hospitalization and subsequent major adverse cardiac events was evaluated in a time dependent Cox proportional-hazard modelling. Of the 18 113 patients in RE-LY, 7200 (39.8%) were hospitalized at least once during a mean follow-up of 2 years. First hospitalization rates were 2312 (39.5%) for dabigatran etexilate (DE) 110, 2430 (41.6%) for DE 150, and 42.6% (N = 2458) for warfarin. Hospitalization was associated with post-discharge death [absolute event rate 9.1% vs. 2.2%; adjusted hazard ratio (HR) 3.6, 95% confidence interval (CI) 3.2-4.0, P < 0.0001], vascular death (adjusted HR 2.9, 95% CI 2.5-3.3, P < 0.0001), and sudden cardiac death (adjusted HR 2.3; 95% CI 1.8-2.9, P < 0.0001). Cardiovascular hospitalization was also associated with an increased risk of post-discharge death (adjusted HR 2.8, 95% CI 2.5-3.2, P < 0.0001), vascular death (adjusted HR 2.8, 95% CI 2.4-3.2, P < 0.0001), and sudden cardiac death (adjusted HR 2.1, 95% CI 1.6-2.7, P < 0.0001) compared with patients not hospitalized for any cardiovascular reason. CONCLUSION: Hospitalizations are associated an increased risk of with death and cardiovascular death in patients with atrial fibrillation."}